Improving Translational Research Outcomes for Opioid Use Disorder Treatments

Area of Science:

• Pharmacology
• Translational Medicine
• Addiction Science

Background:

• Pharmacotherapies are crucial for mitigating harms from opioid use disorder (OUD).
• Translational research for novel OUD medications faces challenges due to addiction's complex nature and limitations of preclinical models.
• Preclinical outcome measures often fail to capture the emotional and cognitive drivers of human opioid use.

Purpose of the Study:

• To review the translational progress of three candidate medications for OUD.
• To identify areas for improvement in translational research strategies for OUD pharmacotherapy.

Main Methods:

• Narrative review of preclinical and clinical studies.
• Analysis of the translational pathway of memantine, lorcaserin, and lofexidine for OUD treatment.

Main Results:

• Memantine, lorcaserin, and lofexidine demonstrated preclinical efficacy.
• Only lofexidine consistently replicated preclinical findings in human trials, leading to FDA approval.
• Preclinical models of opioid self-administration and withdrawal show higher predictive validity for clinical outcomes.

Conclusions:

• Significant discrepancies exist between preclinical predictions and clinical trial effectiveness for OUD medications.
• Clinical trials for OUD pharmacotherapies often suffer from underpowering and imprecise outcome measures.
• Enhancing preclinical target validation and optimizing proof-of-concept study designs are essential for efficient OUD medication development.